Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
iAnthus Capital Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
iAnthus Capital Holdings has been growing earnings at an average annual rate of 12%, while the Pharmaceuticals industry saw earnings growing at 43.8% annually. Revenues have been growing at an average rate of 13.2% per year.
Anahtar bilgiler
12.0%
Kazanç büyüme oranı
50.3%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 23.1% |
Gelir büyüme oranı | 13.2% |
Özkaynak getirisi | n/a |
Net Marj | -36.8% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Improved Revenues Required Before iAnthus Capital Holdings, Inc. (CSE:IAN) Stock's 33% Jump Looks Justified
Sep 10Benign Growth For iAnthus Capital Holdings, Inc. (CSE:IAN) Underpins Stock's 40% Plummet
Jul 26iAnthus Capital Holdings, Inc. (CSE:IAN) Stock Catapults 50% Though Its Price And Business Still Lag The Industry
May 05iAnthus Capital Holdings, Inc. (CSE:IAN) Stocks Pounded By 29% But Not Lagging Industry On Growth Or Pricing
Feb 29iAnthus Capital Holdings, Inc. (CSE:IAN) Stock's 33% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 17Is iAnthus Capital Holdings (CSE:IAN) Using Debt Sensibly?
Feb 28Is iAnthus Capital Holdings (CSE:IAN) A Risky Investment?
Aug 25Gelir ve Gider Dağılımı
iAnthus Capital Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 168 | -62 | 73 | 0 |
31 Mar 24 | 163 | -72 | 77 | 0 |
31 Dec 23 | 158 | -77 | 78 | 0 |
30 Sep 23 | 155 | -102 | 77 | 0 |
30 Jun 23 | 152 | -104 | 81 | 0 |
31 Mar 23 | 157 | -458 | 109 | 0 |
31 Dec 22 | 163 | -449 | 114 | 0 |
30 Sep 22 | 172 | -433 | 120 | 0 |
30 Jun 22 | 182 | -426 | 121 | 0 |
31 Mar 22 | 193 | -68 | 97 | 0 |
31 Dec 21 | 202 | -77 | 97 | 0 |
30 Sep 21 | 201 | -77 | 86 | 0 |
30 Jun 21 | 193 | -87 | 87 | 0 |
31 Mar 21 | 173 | -96 | 87 | 0 |
31 Dec 20 | 152 | -313 | 92 | 0 |
30 Sep 20 | 133 | -547 | 95 | 0 |
30 Jun 20 | 115 | -534 | 103 | 0 |
31 Mar 20 | 99 | -519 | 108 | 0 |
31 Dec 19 | 78 | -305 | 95 | 0 |
30 Sep 19 | 53 | -61 | 85 | 0 |
30 Jun 19 | 32 | -58 | 61 | 0 |
31 Mar 19 | 13 | -84 | 43 | 0 |
31 Dec 18 | 3 | -62 | 35 | 0 |
30 Sep 18 | 0 | -53 | 27 | 0 |
30 Jun 18 | 0 | -45 | 22 | 0 |
31 Mar 18 | 0 | -12 | 14 | 0 |
31 Dec 17 | 0 | -14 | 10 | 0 |
30 Sep 17 | 2 | -8 | 8 | 0 |
30 Jun 17 | 1 | -8 | 7 | 0 |
31 Mar 17 | 1 | -6 | 5 | 0 |
31 Dec 16 | 0 | -5 | 4 | 0 |
30 Sep 16 | 0 | -4 | 4 | 0 |
31 Dec 15 | 0 | -1 | 1 | 0 |
Kaliteli Kazançlar: IAN is currently unprofitable.
Büyüyen Kar Marjı: IAN is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IAN is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.
Büyüme Hızlandırma: Unable to compare IAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: IAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Özkaynak Getirisi
Yüksek ROE: IAN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.